Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The gene therapy developer has followed a $120m round co-led by Novo three weeks ago by filing to go public on the Nasdaq Global Select Market.

Fidelity led a series C round for haematology and cancer therapy developer Antengene, whose corporate shareholders include Celgene, Taikang, Tigermed and WuXi AppTec.

Novo-backed immuno-oncology drug developer Checkmate Pharmaceuticals has filed to go public a month after its last funding round.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

GlaxoSmithKline is paying $176m for a 10% stake in University of Tübingen's RNA drug developer in connection with a strategic partnership agreement.

UC Berkeley-linked cell biology technology developer Berkeley Lights floated in a $178m offering and its shares almost tripled in price on their first day of trading.

The Nikon and Varian-backed cell biology technology developer floated in a $178m offering and its shares almost tripled in price on their first day of trading.

GlaxoSmithKline is paying $176m for a 10% stake in the RNA drug developer in connection with a strategic partnership agreement.

The Roche and GSK-backed autoimmune disease drug developer has gone public in an upsized initial public offering after at least $138m in earlier funding.